TrialCancer medicine2023

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study.

Likun Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.